SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

L773:0270 9139 OR L773:1527 3350
 

Sökning: L773:0270 9139 OR L773:1527 3350 > Fibrosis stage is t...

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

Ekstedt, Mattias (författare)
Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Magtarmmedicinska kliniken
Hagström, Hannes (författare)
Karolinska Institutet,Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Nasr, Patrik (författare)
Linköpings universitet,Avdelningen för kardiovaskulär medicin,Medicinska fakulteten,Region Östergötland, Magtarmmedicinska kliniken
visa fler...
Fredrikson, Mats (författare)
Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten
Stål, Per (författare)
Karolinska Institutet,Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Kechagias, Stergios (författare)
Linköpings universitet,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Region Östergötland, Magtarmmedicinska kliniken
Hultcrantz, Rolf (författare)
Karolinska Institutet,Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
visa färre...
 (creator_code:org_t)
2015-03-23
2015
Engelska.
Ingår i: Hepatology. - : John Wiley & Sons. - 0270-9139 .- 1527-3350. ; 61:5, s. 1547-1554
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background and rationale for the study: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world, strongly associated with insulin resistance and the metabolic syndrome. Nonalcoholic steatohepatitis, i.e. fatty liver accompanied by necroinflammatory changes, is mostly defined by the NAFLD activity score (NAS). The aim of the current study was to determine disease-specific mortality in NAFLD, and evaluate the NAS and fibrosis stage as prognostic markers for overall and disease-specific mortality. Methods: In a cohort study, data from 229 well-characterized patients with biopsy-proven NAFLD were collected. Mean follow-up was 26.4 (± 5.6, range 6-33) years. A reference population was obtained from the National Registry of Population, and information on time and cause of death were obtained from the Registry of Causes of Death. Main results: NAFLD patients had an increased mortality compared with the reference population (HR 1.29, CI 1.04-1.59, p=0.020), with increased risk of cardiovascular disease (HR 1.55, CI 1.11-2.15, p=0.01), hepatocellular carcinoma (HR 6.55, CI 2.14-20.03, p=0.001), infectious disease (HR 2.71, CI 1.02-7.26, p=0.046), and cirrhosis (HR 3.2, CI 1.05-9.81, p=0.041). Overall mortality was not increased in patients with NAS 5-8 and fibrosis stage 0-2 (HR 1.41, CI 0.97-2.06, p=0.07), whereas patients with fibrosis stage 3-4, irrespective of NAS, had increased mortality (HR 3.3, CI 2.27-4.76, p<0.001). Conclusions: NAFLD patients have increased risk of death, with a high risk of death from cardiovascular disease and liver-related disease. The NAS was not able to predict overall mortality, whereas fibrosis stage predicted both overall and disease-specific mortality.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Nyckelord

NAFLD activity score; cohort study; fatty liver; liver fibrosis; mortality

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy